While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market for spinal muscular atrophy (SMA) treatments, Novartis’ research chief Jay Bradner has a ...

Prenatal therapy for spinal muscular atrophy (SMA) with risdiplam has shown promise in a first-of-its-kind study led by Richard Finkel. Roche's Evrysdi has already shown profound benefits in ...

The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA). Spinal muscular atrophy ...

Ladies and gentlemen, thank you for standing by, and welcome to Scholar Rock's first-quarter financial results and business update call. (Operator Instructions) Please be advised that today's ...

Scholar Rock Holding Corp (SRRK), with a market capitalization of nearly $3 billion, released its Q1 2025 earnings, reporting an EPS of -0.67 compared to the forecasted -0.66. Despite the slight ...

Scholar Rock Holding Corp (SRRK), with a market capitalization of nearly $3 billion, released its Q1 2025 earnings, reporting an EPS of -0.67 compared to the forecasted -0.66. Despite the slight miss, ...

Pregnancy outcome is the final result of a fertilization event. Types of pregnancy outcomes include live birth (full term or preterm birth), stillbirth, spontaneous abortion, and induced abortion ...

Prognosis is the prediction of the probable outcome of an individual's current medical condition. A prognosis is made on the basis of the normal course of a disease, the individual's physical and ...

Richard Finkel, MD, a pediatric neurologist at St. Jude Children’s Research Hospital, was included in the Time100 Health list ...

Hence, statement 2 is correct. — Scientists utilised an oral medication called risdiplam, which is prescribed to patients to delay the course of SMA. Risdiplam is normally administered to a patient ...